Metabolic dysfunction-associated steatotic liver disease in people with HIV.
The paper emphasizes the need for tailored approaches to manage MASLD in people with HIV due to its aggressive nature compared to HIV-negative individuals.
Where it sits
this study against the rest of the tesamorelin corpusSummary and findings
This paper reviews metabolic dysfunction-associated steatotic liver disease (MASLD) in people with HIV (PWH), highlighting its prevalence and aggressive clinical course compared to HIV-negative individuals. The role of tesamorelin, a growth hormone-releasing hormone analog, is discussed in the context of MASLD therapies. No specific numeric findings or outcomes were reported in the abstract.
Abstract
<h4>Purpose of review</h4>Metabolic dysfunction-associated steatotic liver disease (MASLD) is highly prevalent among people with HIV (PWH) and increasingly recognized as a major contributor to morbidity and mortality. The field of MASLD is rapidly evolving with adoption of a new nomenclature and approval of the first FDA-approved therapy within the past year. These developments underscore the need to consider the current state of the science specifically in the context of HIV.<h4>Recent findings</h4>MASLD in PWH (MASLD-HIV) follows a more aggressive clinical course compared to HIV-negative individuals. While MASLD-HIV shares common pathogenic mechanisms with MASLD in the general population, HIV-specific factors - including altered body composition, chronic immune activation, enhanced gut permeability, and antiretroviral therapy - exacerbate disease progression. Despite an expanding pipeline of MASLD therapies, a critical gap remains in evaluating these interventions specifically among PWH. Nonetheless, dedicated studies of glucagon-like peptide-1 receptor agonists and the growth hormone-releasing hormone analog tesamorelin have shown promise in MASLD-HIV.<h4>Summary</h4>MASLD is a key contributor to liver-related and cardiovascular-morbidity in PWH. While there have been exciting advances to improve diagnosis and management of MASLD in the general population, differences in MASLD pathophysiology demonstrate the need to tailor our approach specifically for PWH.
Background
The paper addresses the prevalence of metabolic dysfunction-associated steatotic liver disease in people living with HIV, a condition that has been increasingly recognized in this population. Prior studies have suggested a link between HIV and liver disease, but the specific role of tesamorelin in this context remains unclear. This study aims to shed light on the metabolic implications of HIV and potential interventions.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
Not reported in abstract.
Key findings
- Not reported in abstract.
Limitations
- Not reported in abstract.